Clinical trial
Evaluation of Neutrophil Gelatinase-associated Lipocalin (NGAL) in Early and…
NCT00445809 · Abbott RDx Cardiometabolic, Other · Completed
Key facts
| NCT number | NCT00445809 |
|---|---|
| Title | Evaluation of Neutrophil Gelatinase-associated Lipocalin (NGAL) in Early and Evolving Acute Kidney Injury |
| Official title | EValuation Of NGAL in Early and eVolving Acute kidnEy Injury |
| Acronym | EVOLVE |
| Lead sponsor | Abbott RDx Cardiometabolic, Other |
| Status | Completed |
| Study type | Observational |
| Conditions | Kidney Failure, Acute |
| Enrollment | 355 |
| Start date | Feb 1, 2007 |
| Primary completion | Dec 1, 2008 |
| Completion | Apr 1, 2009 |
| First posted | Mar 9, 2007 |
| Last update posted | Aug 4, 2009 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: